Ocelot Bio

📍 Redwood City, United States🗓 Founded 2020👥 20 employees💰 Last funded 2021
Biotechnology Research🌐 ocelotbio.com
Website LinkedIn
Ocelot Bio is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics designed to significantly improve outcomes for patients with liver disease. The company’s lead clinical candidate, OCE-205, is a therapeutic peptide with a mechanism of action designed to selectively address portal hypertension induced complications of end-stage liver disease (ESLD). These complications include hepatorenal syndrome with acute kidney injury (HRS-AKI) and ascites, both of which may lead to serious and life-threatening outcomes. Ocelot Bio has initiated a Phase 2 clinical trial of OCE-205 in HRS-AKI, and the U.S. Food & Drug Administration (FDA) has granted OCE-205 Orphan Drug Designation in the treatment of hepatorenal syndrome. The company was founded by leading experts in therapeutic peptide development and is backed by a strong syndicate of investors including Venrock, RA Capital Management and Vivo Capital. For more information, visit www.ocelotbio.com.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2020
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Ocelot Bio?
Ocelot Bio has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Ocelot Bio last raise funding?
The most recent investment in Ocelot Bio recorded on gritt.io was in 2021.
When was Ocelot Bio founded?
Ocelot Bio was founded in 2020.
What industry is Ocelot Bio in?
Ocelot Bio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Ocelot Bio based?
Ocelot Bio is headquartered in Redwood City, United States.